Latest Breaking News On - Addressing sickle cell disease - Page 7 : comparemela.com

Emmaus Life Sciences Announces Bahrain Temporary License of Endari®

Emmaus Life Sciences Announces Bahrain Temporary License of Endari®
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Saudi arabiaUnited statesKingdom of bahrainYutaka niiharaGeorge sekulichCenters for diseaseProducts regulation departmentCommittee on addressing sickle cell diseasePrnewswire emmaus life sciences incDrug administrationExchange commissionNational center on birth defectsBlueprint for action national academy of sciencesNational health regulatory authorityEmmaus life sciencesEmmaus life sciences inc

Emmaus Life Sciences Announces Bahrain Temporary License of Endari®

/PRNewswire/ Emmaus Life Sciences, Inc. (OTC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,.

Saudi arabiaUnited statesKingdom of bahrainYutaka niiharaGeorge sekulichCenters for diseaseProducts regulation departmentCommittee on addressing sickle cell diseasePrnewswire emmaus life sciences incDrug administrationExchange commissionNational center on birth defectsBlueprint for action national academy of sciencesNational health regulatory authorityEmmaus life sciencesEmmaus life sciences inc

Emmaus Life Sciences Announces Bahrain Temporary License of Endari®

Emmaus Life Sciences Provides SEC Reporting Update

Similarly, any earnings releases and other press releases and investor communications containing information derived from such financial statements should no longer be relied upon. Emmaus also provided an update on the filing of its delinquent quarterly reports.

United statesWillis leeYutaka niiharaCenters for diseaseCommittee on addressing sickle cell diseaseCompany contactExchange commissionNational center on birth defectsBlueprint for action national academy of sciencesEmmaus life sciencesEmmaus life sciences incLife sciencesAnnual reportChief executive officerReported netEmmau japanese

Emmaus Life Sciences Provides SEC Reporting Update

/PRNewswire/ Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in sickle cell disease treatment, announced today that it has restated its financial.

United statesYutaka niiharaCenters for diseaseCommittee on addressing sickle cell diseasePrnewswire emmaus life sciences incExchange commissionNational center on birth defectsBlueprint for action national academy of sciencesEmmaus life sciencesEmmaus life sciences incLife sciencesAnnual reportChief executive officerReported netEmmau japaneseQuarterly reports